Clinical Trial Update: A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating PQ912 for early Alzheimer's disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PQ912

Snippet

Sponsor: Vivoryon Therapeutics N.V. | Conditions: Alzheimer Disease | Phase 2 | Status: TERMINATED | Results posted: 2025-12-12